An accomplished healthcare industry executive, Bob Altman’s career reflects success in leading teams that consistently achieve aggressive corporate goals in both mature and emerging biotech and pharmaceutical businesses. His management experience spans commercialization, product and clinical development, medical affairs, regulatory affairs and quality assurance, compliance, manufacturing, life-cycle management and creation of highly successful strategic alliances for drug products and medical devices.

Most recently, Bob has been appointed as an Adjunct Professor of Entrepreneurship at the Booth School of Business at The University of Chicago where he created and teaches a new class titled “Entrepreneurship for Science and Medicine”. He also serves as an Entrepreneur in Residence at the Polsky Center for Entrepreneurship and Innovation at The University of Chicago.

Before his professorship, Bob served as President of Pinnacle Biologics, Inc., a subsidiary of Concordia Healthcare (TSX: CXR; NASDAQ: CXRX). Pinnacle is a fully integrated specialty pharmaceutical company that develops, manufactures and commercializes ultra-orphan oncology drugs, oncology support drugs, and medical devices. Bob led the commercial strategy and global execution of the product portfolio, and the growth strategy for strategic acquisitions and partnerships. He had joined the company in 2012 as Chief Commercial Officer.

Bob previously founded and built a fully integrated specialty pharmaceutical company, Marathon Pharmaceuticals, and led the company as CEO and President from 2007 to 2012. He spearheaded the company’s product development efforts and added to the portfolio and re-launched complementary products driving revenue growth and a multi-fold increase in profitability.

From 2006 to 2007, Bob served as SVP Marketing and Sales for Astellas Pharma US company’s $1.8 billion U.S. operations, directing a team of approximately 1,050 staff and sales professionals, and exceeding 20% annual revenue growth for product lines under his leadership. In an earlier Astellas role as Vice President Marketing and Sales from 2004 to 2006, he led sales of urology and primary care products. Bob was an integral part of the leadership team that launched Astellas in North America following the merger of Yamanouchi and Fujisawa organizations.

Bob’s earlier career included numerous leadership positions over 17 years at Abbott Laboratories. As Vice President General Manager of the Cardiovascular Drug Franchise from 1998 to 2004, he led marketing, Phase IV R&D, and life-cycle management of this business, delivering notable successes that included two strategic partnerships and execution of a strategy that positioned two products on track to generate revenue of more than $1 billion. Among other key roles over 17 years at Abbott included Vice President Marketing for five business units representing more than $2.6 billion in sales and Vice President for the company’s Managed Health Care business.

Additional experience includes product management roles with Alnor Instrument Company and Perkin-Elmer Corporation.

Bob currently serves on the Board of Directors for: Toltec Pharmaceuticals - a pipeline pharmaceutical company developing novel therapies that address niche markets exclusive to women’s health, Preora Diagnostics - a diagnostics company developing low-cost, minimally invasive and highly sensitive cancer pre-screening tests using technology that detects and measures cellular changes at the nanoscale level, Output Medical - a medical device company that will advance the standard of care for acute kidney injury and dialysis management.

Bob earned an MBA in Finance and Marketing from the Booth School of Business, University of Chicago, having earlier received both Ph.D. Physical Chemistry and MA Chemistry degrees at Harvard University, and a BS Chemistry at the University of California, Riverside.